95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study

• Published in: Diabetes (New York, N.Y.) Vol. 72; no. Supplement_1; p. 1
• Main Authors: WU, JINGYING, HU, WEI, DU, YIJUN, ZHANG, QIAN, ZHOU, RENPENG, ZHANG, QIN, QIN, HUILING, YE, ZI, XU, YIMEI, FENG, SHENG, SHU, CHANG, SHEN, YU, FAN, YANG
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 20.06.2023
• Subjects: Agonists; Body mass index; Body weight; Clinical trials; Dosage; Food availability; Food consumption; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucose tolerance; Insulin secretion; Metabolic syndrome; Pharmacodynamics; Pharmacokinetics; Placebos; Safety; Titration; Vomiting

Background: HRS-7535, a novel, oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist, has demonstrated no strict food restriction, and has been found to obviously improve glucose tolerance, promote insulin secretion, and reduce food consumption in preclinical studies. This study aime...